The first 2-drug complete regimen for HIV-infected patients who have never taken ART
The US Food and Drug Administration has approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received tr
To continue reading this article
Continue reading your article with a eMediNexus account.